GLP-1 Weight Loss Medications
Low-Cost Laboratory Testing
Diet & Exercise Coaching
Body Composition Testing
On-Demand Physician Access

*Telemedicine services available in Texas. In-person services provided in Arlington. Laboratory testing available nationwide.

Voafit offers effective tools to help YOU achieve a healthy, fit body and keep it for life:

  • GLP-1 Weight Loss Meds

  • Low-Cost Lab Testing

  • Diet & Exercise Coaching

  • Body Composition Testing

  • 24/7 Physician Access

Schedule a free consult with board-certified M.D. and certified fitness instructor Dr. Ian Justl Ellis today!

Our Services

Our Services

Medication Pricing

Schedule a free consultation with Dr. Justl Ellis to confirm treatment eligibility.

Success Stories

GLP-1 FAQ

Patients taking semaglutide lose an average of 16% of their body weight, and patients taking tirzepatide lose an average of 22.5% of their body weight, compared to just 2.4% weight lost in the placebo group. Jastreboff, A.M. et al. Tirzepatide once weekly for the treatment of obesity. NEJM 2022 and Garvey, W.T. et al. Two-year effects of semaglutide in adults with overweight or obesity; Nat Med 2022

  • GLP-1 agonist medications are a genuinely revolutionary class of medications that put achieving a healthy body weight within reach for most people.

    The most well known of these medications, and the most affordable, is semaglutide (commonly sold under the brand names Ozempic® and Wegovy®).

    A new medication called tirzepatide (brand name Mounjaro®) is also available. This medication binds to an additional receptor called the glucose-dependent insulinoptropic polypeptide (GIP), intensifying its treatment effect.

  • Both semaglutide and tirzepatide bind to the glucagon-like-peptide 1 (GLP-1) hormone receptor found in the human gut.

    This has many beneficial effects, but primary among them is extremely potent appetite suppression and dramatic slowing of emptying of the stomach—eliminating cravings and causing a rapid reduction in body weight.

    Tirzepatide is a second generation medication which binds to an additional receptor called the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual-receptor action results in even more dramatic results.

    Our formulations of both semaglutide and tirzepatide are compounded with pyridoxine (also known as vitamin B-6), which helps decrease unwanted gastrointestinal side effects such as nausea.

  • Semaglutide:

    An average patient taking semaglutide will lose 16% of their body weight—nearly 7x more than with lifestyle interventions alone.

    Put another way, the average 200 pound patient can expect to lose 30-35 pounds or more during a course of treatment.

    Tirzepatide:

    An average patient taking tirzepatide will lose a remarkable 22.5% of their body weight—nearly 10x more than with lifestyle interventions alone.

    The average 200 pound patient could expect to lose 45 pounds or more during a course of these medications.

    Additional treatment effects:

    Patients taking GLP-1 agonists also show dramatic improvements in waist circumference, blood sugar and blood pressure levels, and overall level of physical function—as well as a significant reduction in risk of adverse cardiac events such as heart attack.

  • Side effects of GLP-1 medications are generally mild, and most can be decreased or eliminated by careful adjustment of your diet under the supervision of Dr. Justl Ellis.

    The most commonly experienced side effects are nausea and diarrhea. Occasionally, moderately severe side effects such as stomach pain and vomiting may occur.

    Very severe or life-threatening side effects are very rare but can occur.

    Comprehensive information on GLP-1 medications written for patients, including efficacy data, contraindications, and a full list of potential side effects, may be accessed via this document from the Department of Texas Health and Services.

    FDA prescriber information data sheets for semaglutide may be accessed here.

    FDA prescriber information data sheets for tirzepatide may be accessed here.

  • Semaglutide and tirzepatide are both administered via subcutaneous injection (under the skin) once a week.

    A syringe kit with complete instructions of how to draw up and self-administer the medication will be shipped to you with your first medication delivery.

    Administration of the medication by Dr. Justl Ellis at our facility is complementary when done at the same time as any other in-person Voafit service.

  • Drug compounding is the process of combining, mixing, or altering ingredients to create a medication tailored to the needs of an individual patient.

    Our formulations of both semaglutide and tirzepatide are compounded with pyridoxine (also known as vitamin B-6), which helps decrease unwanted gastrointestinal side effects such as nausea.

    Our compounded medications contain the same active pharmaceutical ingredient as “name brand” medications and are available at a significantly lower cost.

    We obtain our medications from Grand Avenue Pharmacy, a licensed compounding pharmacy in Austin, Texas.

  • Yes, you can!

    We ship compounded semaglutide / pyridoxine and tirzepatide / pyridoxine directly to your door from our pharmacy partner at a fraction of the cost of “brand name” medications.

    Semaglutide is the more affordable of the two options. Many people recoup the entire cost of semaglutide treatment via lower food costs alone.

    Tirzepatide / pyridoxine is a premium option and is available to those wishing to spend more for the best possible results.

    You may use Health Savings Account (HSA) funds to pay for Voafit services.

  • We do not accept commerical insurance. However, you may use Health Savings Account (HSA) funds to cover your membership cost.

  • Yes! You may use Health Savings Account (HSA) funds to cover your membership cost—and many people recoup the entire cost of their membership via lower food costs alone.

  • Comprehensive information on GLP-1 medications written for patients, including efficacy data, contraindications, and potential side effects, may be accessed via this document from the Department of Texas Health and Services.

    FDA prescriber information data sheets for semaglutide may be accessed here.

    FDA prescriber information data sheets for tirzepatide may be accessed here.

    Treatment effects for semaglutide were first described in this 2021 study in the New England Journal of Medicine. These findings were confirmed in the STEP 5 Trial published in Nature Medicine in 2022.

    Treatment effects for tirzepatide were first described in this 2022 study, also published in the New England Journal of Medicine.

    Multiple trials showing reduction in risk of adverse cardiac events such as heart attack in patients taking GLP-1 agonist medication may be reviewed here and here.

    Further resources are available on request.

About Dr. Justl Ellis

Dr. Ian Justl Ellis is a board-certified physician with a doctorate from the University of Colorado School of Medicine. He completed a residency in Emergency Medicine at Mount Sinai St. Luke’s-Roosevelt Hospital in New York, and completed a fellowship in Medical Education at John Peter Smith Hospital in Fort Worth.

He graduated summa cum laude from Union University in Jackson, Tennessee with an undergraduate major in Athletic Training and minors in Biology and Psychology.

He is also a Personal Fitness Instructor certified by the International Fitness Professionals Association, and has served clients of all ages and fitness levels as a personal trainer and nutrition expert since early in his college career.

Have questions? Dr. Justl Ellis may be contacted directly via text message at (817) 583-8542 or via email at md@voafit.com.